Yes another great result. Looks like its miles above expectations but as Charlie rightly points a good chunk of profit there is the non-recurring settlement. Management states that full year profits will meet previous guidance so the acquisition is performing well.
The next thing to look for is that they manage the working capital back down as a sign of integrating Teva effectively.
